Repligen financial statements require restatement due to revenue recognition error

Artifacts Images/DigitalVision via Getty Images Repligen ( NASDAQ: RGEN ) said it will need to restate some of its financial statements after a review found that the timing of recognition of product revenue from a COVID-related cancellation payment was recognized inappropriately. The error has impacted financial statements for the.